Variable | Category | Frequency | Percentage |
Gender | Female | 5942 | 61.34 |
Male | 3745 | 38.66 | |
Age (IQR) | 40 (33–45) | ||
Age category | 15–19 | 128 | 1.32 |
20–24 | 193 | 1.99 | |
25–29 | 684 | 7.06 | |
30–34 | 1715 | 17.70 | |
35–39 | 2107 | 21.75 | |
40–44 | 2042 | 21.08 | |
45–49 | 1215 | 12.54 | |
50+ | 1603 | 16.55 | |
Facility ownership | Government | 9188 | 94.85 |
Non-governmental organisations | 494 | 5.10 | |
Private | 5 | 0.05 | |
Facility type | Clinic | 11 | 0.11 |
Health centre | 2273 | 23.46 | |
Primary hospital | 996 | 10.28 | |
General hospital | 5389 | 55.63 | |
Referral hospital | 857 | 8.85 | |
Other | 161 | 1.66 | |
Service provided in a military facility | No | 9328 | 96.29 |
Yes | 359 | 3.71 | |
Pregnant mother | No | 5908 | 99.43 |
Yes | 34 | 0.57 | |
Lactating mother | No | 5864 | 98.69 |
Yes | 78 | 1.31 | |
WHO stage | I | 8750 | 90.33 |
II | 372 | 3.84 | |
III | 248 | 2.56 | |
IV | 317 | 3.27 | |
Adherence | Poor | 164 | 1.69 |
Fair | 392 | 4.05 | |
Good | 9131 | 94.26 | |
Viral test reason | Routine first VL | 5790 | 59.77 |
Routine annual VL | 3063 | 31.62 | |
Suspected clinical ART failure | 26 | 0.27 | |
Suspected immunological ART failure | 62 | 0.64 | |
Suspected ART failure on initial VL | 586 | 6.05 | |
Not indicated in the form | 160 | 1.65 | |
Recent VL status | Suppressed | 6950 | 71.75 |
Non-suppressed | 2737 | 28.25 | |
Drug regimen | 1c (AZT-3TC-NVP) | 3138 | 32.39 |
1d (AZT-3TC-EFV) | 1027 | 10.60 | |
1e (TDF-3TC-EFV) | 4133 | 42.67 | |
1f (TDF-3TC-NVP) | 1194 | 12.33 | |
1g (ABC-3TC-EFV) | 5 | 0.05 | |
1h (ABC-3TC-NVP) | 4 | 0.04 | |
2a (ABC-ddl-LPV/r), 2c (TDF-ddl-LPV/r), 2d (TDF-ddl-NFV) and 2g (TDF-3TC-LPV/r) | 7 | 0.07 | |
2f (AZT-3TC-ATV/r) | 49 | 0.51 | |
2h (TDF-3TC-ATV/r) | 130 | 1.34 | |
Treatment line | First line | 9501 | 98.08 |
Second line | 186 | 1.92 |
ABC, abacavir; ART, antiretroviral therapy; ATV/r, atazanavir/ritonavir; AZT, azidothymidine; ddl, didanosine; EFV, efavirenz; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; NVP, nevirapine; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; VL, viral load.